A method is provided for treating schizophrenia in a mammalian species by administering an ACE inhibitor, such as captopril, alone or with a neuroleptic such as cholecystokinin, fluphenazine or haloperidol.

A process is disclosed for direct isolation of captopril from a substrate of the formula wherein R is lower alkyl or lower alkoxy. In this process, the substrate is first treated with an aqueous alkali metal hydroxide capable of forming a water-soluble salt of the substrate, wherein the alkali metal hydroxide has a concentration of 4 M or greater. The substrate is then neutralized, preferably with a mineral acid. By this process, captopril may be directly crystallized from an aqueous solu...

S-enantiomers of the formulaI result from the reaction of a racemic form of compound I with an alcohol in the presence of an enzyme capable of selectively esterifying the R-enantiomers of the racemic compound.S-enantiomers of the formulaI result from the reaction of a racemic form of compound I with an alcohol in the presence of an enzyme capable of selectively esterifying the R-enantiomers of the racemic compound.

NEW PHARMACEUTICAL COMPOSITIONS IN THE FORM OF BEADLETS AND METHOD A pharmaceutical composition is provided which is in the form of a plurality of beadlets, adapted to be filled into pharmaceutical hard shell capsules, or compressed into tablets, which beadlets are formed of a pharmaceutical such as an ACE inhibitor, for example, captopril, a beta-blocker such as nadolol, propranolol or atenolol, a calcium channel blocker such as diltiazem or nifedipine or other pharmaceuticals including combina...